2798-50-7

Upstream product

• 139600-16-1 C₁₃H₁₇NO₄ 
• 101-41-7 benzeneacetic acid methyl ester 
• 103-82-2 phenylacetic acid 
• 72-19-5 L-threonine 
• 103-80-0 phenylacetyl chloride 

Downstream Products

• 116912-19-7 N-(Phenylacetyl)-L-threonyl-L-alanin-tert-butylester 
• 82933-35-5 Sulfuric acid mono-((2S,3S)-2-methyl-4-oxo-3-phenylacetylamino-azetidin-1-yl) ester; compound with pyridine 
• 82933-33-3 N-((2S,3S)-1-Benzyloxy-2-methyl-4-oxo-azetidin-3-yl)-2-phenyl-acetamide 
• 82951-08-4 (2S,3S)-3-Hydroxyamino-2-phenylacetylamino-butyric acid 
• 82933-31-1 (3S-trans)-1-Hydroxy-4-methyl-3-[(phenylacetyl)-amino]-2-azetidinone 
• 82933-32-2 N-(phenylacetyl)-L-threonine O-benzylhydroxyamide 
• 72-19-5 L-threonine 

Relevant academic research and scientific papers

Design, synthesis, and cytotoxicity evaluation of threonine-based galactoceramide with aromatic groups and various fatty-acyl side chains

Abstract: In galactoceramides, presence of fatty-acyl group on amide moiety or phytosphingosine group is some of the important features that influence the cytotoxicity. Continuous efforts are in progress to modify the fatty-acid moiety and phytosphingosine group present on the galactoceramides to enhance the cytotoxic potential of these compounds. Hence, in the present study, threonine-based β-galactoceramide and its derivatives were prepared by modifying the fatty-acyl group on amide moiety with different fatty-acyl moieties and aromatic acids employing trichloroacetimidate methodology. The structurally related threonine-based ceramide part was synthesized in multi-step process using different reagents. The ceramide part was glycosylated with galactose using trichloroacetimidate as donor. Further, all the synthesized compounds were evaluated for in vitro cytotoxicity against three cancer cell lines and one normal cell line and all the compounds exhibited good to moderate cytotoxicity against all the tested cancer cell lines. In aromatic derivatives, the compound 8i exhibited promising activity against MCF7, A549 and HeLa cancer cell lines with IC50 values of 14.08, 14.78, and 16.70 μM, respectively. In fatty-acid derivatives, two compounds exhibited promising activity, i.e., compound 8m against HeLa with IC50 value 16.34 μM and compound 8n against MCF7 with IC50 value 18.05 μM. Based on structure–activity relationship, aromatic acid derivatives exhibited potential activity as compared to fatty-acid derivatives. Further, the influence of some of the key factors such as spacer chain length between aromatic residue and amide functional group, methoxy substituents on aryl group, terminal unsaturation of fatty acid and branching chain effect on the cytotoxicity are discussed.

COSMETIC USES AND METHODS FOR INDOLINE GRANZYME B INHIBITOR COMPOSITIONS

Cosmetic uses and methods for indoline granzyme B inhibitor compounds in compositions with a cosmetically acceptable carrier. Uses and methods for treating, reducing or inhibiting the appearance of ageing in the skin are provided. Also provided are compositions and formulation for cosmetic uses and methods of maintaining a youthful appearance, reducing an appearance of ageing, inhibiting an appearance of ageing, reducing a rate of an appearance of ageing, reducing a skin inelasticity, reducing a rate of increasing skin inelasticity, maintaining a skin elasticity, and increasing the density of hair follicles of a skin of a subjecl. The uses and methods comprise applying/administering an indoline granzyme B inhibitor to a skin, or a portion of a skin of the subject.

Synthesis and assignment of stereochemistry of the antibacterial cyclic peptide xenematide

The synthesis of the antimicrobial cyclic peptide xenematide was accomplished by Fmoc solid phase peptide synthesis and the key esterification reaction was achieved using a modified Yamaguchi esterification. Comparison of the optical rotation and NMR data